ScreenerHero

KYNB Kyntra Bio, Inc.

NAS · US · Healthcare · Biotechnology · kyntrabio.com
6.130USD+2.85%Mkt Cap: 24.82M $P/E: —

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap24.82M USD
Enterprise Value-45.19M USD
Revenue (TTM)4.62M USD
Gross Profit5.88M USD
Net Income (TTM)183.45M USD
Revenue/Share1.14 USD
Last Price6.130 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.42
PEG—
EV/EBITDA0.90
EV/Revenue-9.79
P/S5.23
P/B-0.80
EPS (TTM)-7.53
EPS (Forward)-14.23
52W Range
5.6207% of range12.58
52W High12.58 USD
52W Low5.620 USD
Profitability
Gross Margin91.37%
Oper. Margin1191.52%
EBITDA Margin0.00%
Profit Margin2848.63%
ROE-610.73%
ROA153.40%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.77M USD
CapEx (TTM)38.00K USD
FCF Margin1171.46%
FCF Yield217.86%
Net Debt-91.32M USD
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity—
Current Ratio2.69
Quick Ratio2.54
Book Value/Sh-7.45 USD
Cash/Share22.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 17, 2025
Analyst Consensus
Rating—
Target (Mean)39.67 USD
Upside (mean)+547.1%
Target Range35.00 USD – 43.00 USD
35.00+547.1% to mean43.00
# Analysts3
Ownership
Shares Out.4.05M
Float3.57M
Insiders2.02%
Institutions24.68%
Short Interest
Short Ratio4.3d
Short % Float2.54%
Short % Out.2.49%
Shares Short100.71K
Short (prev mo.)98.20K
Technical
SMA 507.330 (-16.4%)
SMA 2007.447 (-17.7%)
Beta1.05
S&P 52W Chg16.45%
Avg Vol (30d)26.23K
Avg Vol (10d)28.09K
Technical Indicators
RSI (14)29.5
MACD-0.3809
MACD Signal-0.2365
MACD Hist.-0.1444
BB Upper8.530 USD
BB Middle7.104 USD
BB Lower5.678 USD
BB Width40.15%
ATR (14)0.3901 USD
Vol Ratio (20d)0.60x